home > ict > winter 2013 > mind your language
International Clinical Trials

Mind Your Language

The question of how pharmaceutical R&D and clinical supplies organisations control source data for local languages is currently one of the biggest issues facing clinical trial labelling and packaging. Companies are struggling to find a reliable way of approving and locking down local language data – leading to the ever-present risk of products being incorrectly labelled, causing financial implications and risk to patient health.

Clinical trials are, of course, a global activity. As such, trial materials are now shipped across various countries and continents. Labelling, booklets and, where necessary, instructions for use must therefore be safely and accurately customised, not only so they are in the appropriate local languages, but also to ensure that the nuances of individual languages are understood appropriately to communicate coherently with clinicians and patients.

They must also comply with country-specific requirements; in certain countries, additional information, such as the name of the trial organisation or specific medication disposal notices, has to be stated by law.

There is currently a huge degree of inconsistency in how organisations across the sector are approaching this important issue. Where companies have developed in-house processes, there is often a number of disparate systems involved in managing language, label/booklet design, approvals and final printing. Conversely, some organisations still rely on onerous manual processes – at great cost in terms of manpower and money.

This industry-wide multiplicity of approaches to clinical trial labelling is building avoidable inefficiencies into the supply chain, leading to an increase in quality checks, the deceleration of product to market and, in the process, an escalation in development costs. Continuing with such an inconsistent and variable approach as trials become more complex is no longer sustainable.

The clinical trial sector – as well as trial participants – would undoubtedly benefit from adopting a more uniform, consolidated approach to labelling. The challenge is both global and ubiquitous. Pharmaceutical manufacturers, clinical supplies companies and supply chain experts must therefore collaborate to bring disparate processes together into a single secure, version-controlled and auditable process to manage every stage of the label lifecycle management – from the physical translation and storage of phrases, design of labels and booklets, to the actual final printing and verification.

By implementing a single-solution strategy, organisations can reap the benefits of removing errors, reducing quality checks and eliminating the unnecessary and costly return of materials. As pharmaceutical companies battle to contain rising development costs, improve efficiencies and increase return on investment, integrated label lifecycle management can make a key contribution to some of the industry’s biggest operational goals.

Current Environment

The supply chain journey for clinical trials materials is a complex and variable process. Treatments, comprising various percentages and levels of a drug and placebo, are packaged to be distributed to clinical trial centres for eventual use with trial participants. The packaging and labelling are handled either by the pharmaceutical R&D organisation itself, a clinical supplies company, or a combination of the two.

However, with trials now being conducted on a global scale, the ultimate recipient may be located anywhere in the world. Moreover, both the person administering the trial and the logistics stakeholders responsible for the drug’s safe and appropriate delivery will most likely speak a different language. Attaching the right label – and, more specifically, the accurate correlation of the right recipient with the right dosage levels – is critical.

In fact, such is the significance of this part of the process, use of the term ‘label’ is perhaps misleading. In this instance, labelling is much more than the simple communication of addressee details; it is the platform for the delivery of key information that is crucial to the safe and appropriate transportation and administration of high-value medicines, leading to the reliable monitoring of their effects on patients.

More often than not, ‘labels’ are actually 40- to 50-page booklets – covering a similar volume of local languages – that are affixed to trial materials via an adhesive-backed booklet. These booklets are printed in bulk, with critical variable information, such as the patient’s name, product use-by date or a patient’s identification number, overprinted on the front page.

Country-Specific Design

In a multi-country, multi-language clinical trial environment, managing such a comprehensive range of variable data is a huge issue. To achieve the timely, safe and cost-efficient delivery of materials to a global user-base, companies face a number of challenges. Primarily, they must not only ensure that information is presented in the native language of its intended recipient, but also that translations – most often from English into a local language – capture the subtleties and nuances of that local language.

When creating and managing a database of phrases, and ensuring they are translated appropriately and integrated effectively into the version control process, the storage and approval of local language data is key.

In addition, there is a large amount of local legislation around country-specific label design. For example, information requirements in Germany are much greater than in some other parts of Europe. As a result, single-panel labelling in that country will, by law, need to be different. This creates additional data, all of which needs managing effectively. Companies have various systems in place to manage this – some of which are very good – but few, if any, are joined up. Pharmaceutical companies need to do more checks throughout the process, with cost implications in terms of time and expense.

Optimising Technology

The pharmaceutical sector is heavily regulated. Companies work hard to mitigate risk and ensure quality control, and comprehensive standard operating procedures, understandably, mean they conduct frequent and rigorous checks to maintain compliance.

However, there are existing tools and techniques that can be optimised to provide a proven and reliable way of versioning control and managing data – at the same time, reducing the number of checks companies need to conduct and delivering significant efficiency gain.

Once they have aggregated and consolidated local language data and country-specific label design requirements, companies need to output it to a single-panelled label for print, or put it in a format that can be picked up by a third party that can print the booklets without having to go through further onerous checks.

This final aspect is crucial, with errors at the printing stage likely to be most costly. More effective use of technology can help provide companies with secure access to information in the system at every stage through the process – enabling stakeholders to monitor progress, evaluate quality and inspect print outputs.

A creased print ribbon or poor ink quality can lead to unreadable barcodes or incompliant documentation, which can mean high volumes of product returns. In cases where drugs have a short shelf-life, this can mean that by the time relabelling has taken place, the treatment is out-of-date, and needs to be thrown away and remade.

Labelling errors can therefore have extremely costly implications. The use of technology that provides secure, remote system access can give companies greater visibility, control and confidence that all aspects of the process have been managed effectively.

Lifecycle Efficiencies

The packaging and labelling process could undoubtedly be much more efficient. Historically, companies have managed the design, data management and print processes as three disparate areas – and built in multiple manual visual checks to ensure quality control. To progress, however, the industry could adopt a more integrated approach, underpinned by robust and reliable automated processes.

Holistic systems can capture and manage data right across a trial, and bring it all together at the right time. Moreover, in an industry committed to accelerating the speed and containing the cost of drug discovery, integrated web-based solutions that support an end-to-end process – including automated post-print vision inspection – will provide a strong platform for the natural introduction of ‘just in time’ printing. This will further reduce the need, and associated cost, to print multi-language labels and booklets in bulk.

Tools that provide management across the labelling lifecycle can reduce the unnecessary duplication of checks, further mitigate risk and significantly improve return on investment. For industry stakeholders in clinical supplies operations, the question is a simple one: are you doing enough to drive efficiencies and increase cost savings throughout the labelling process?

The answer will most likely come through taking a collaborative approach to an industry-wide challenge, and optimising technology to deliver a single secure, version-controlled and auditable process to manage the entire label lifecycle.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.

About the author

Vince Postill is Senior Vice President of Global Business Development at PRISYM ID. He is tasked with building strategic relationships with key partners to increase market share by building compelling joint value propositions with the company’s software, as well as establishing joint venture relationships. Before joining PRISYM ID in 2004, Vince worked for a number of auto-ID companies.

Vince Postill
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?


Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement